Five HTA bodies only evaluated evolocumab. Interestingly, TLV in Sweden revisited its initial negative recommendation on evolocumab into a restricted positive recommendation for patients with high risk of cardiovascular events after it received an updated economic analysis.
Out of 21 assessments, 16 mentioned the lack of results on hard endpoints as a negative driver and 8 criticised the lack of long-term safety data (Table 4) . Five HTA bodies remarked that PCSK9 inhibitors are currently not cost-effective for the majority of patients, mainly due to estimations on predicted reductions in hard cardiovascular outcomes in the underlying economic analysis.
HTAs on evolocumab and alirocumab were identified using Quintiles' HTA Accelerator platform 1 . Analysis of the HTAs was performed focusing on decision drivers for recommendations in terms of clinical benefit, economic outcomes and patient populations. Evolocumab and alirocumab are the first two PCSK9 inhibitors that have been granted access by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), with both drugs receiving a marketing authorisation mid-2015. Both drugs represent a new cholesterollowering drug class used for the prevention of cardiovascular diseases and both drugs show promising results with high efficacy in low-density lipoprotein cholesterol (LDL-C) reduction and acceptable short-term tolerability. Health technology assessment (HTA) bodies however show concern about the budget impact these costly drugs have considering the high prevalence of cardiovascular disease and lack of clinically relevant outcomes and long-term safety data. This research investigated HTA recommendations and key decision drivers for evolocumab and alirocumab in primary hypercholesterolaemia and mixed dyslipidaemia.
DRIVERS IN HTA DECISION-MAKING FOR CHOLESTEROL-LOWERING PCSK9 INHIBITORS
Evolocumab was studied in four phase III studies which showed that evolocumab significantly improved mean percentage change in LDL-C from baseline to week 12 versus ezetimibe (38%-47% reduction) and placebo (55%-76% reduction) 2 . Alirocumab was studied in the ODYSSEY clinical study program which showed that alirocumab significantly reduced LDL-C from baseline to week 24 versus ezetimibe (24%-36% reduction) and placebo (20%-64% reduction) 2 . The effect of both drugs on cardiovascular morbidity and mortality has not been determined.
Until September 2016, 25 HTAs were published on evolocumab and/or alirocumab including 21 HTA decisions, as outlined in Table 1 . Nine HTA bodies assessed both drugs, of which six HTA bodies gave the same recommendation, three gave a different recommendation. Alirocumab received a negative recommendation from HAS (France), whereas evolocumab received a restricted positive recommendation. SMC (Scotland) and INESSS (Canada) both gave a restricted positive recommendation on alirocumab; SMC gave a negative recommendation on evolocumab while INESSS gave a positive recommendation. 
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